CTU: A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-Risk Muscle-Invasive Urothelial Carcinoma Post-Radical Resection

  • Zhang, Alison (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleV940-005
AcronymV940-005
StatusActive
Effective start/end date12/03/2428/02/29